| sofosbuvir/velpatasvir / Generic mfg. |
2017-004044-37: Bioavailability and food effects of the pediatric formulation of SOF/VEL in adult subjects. |
|
|
| | 1 | 194 | US | Epclusa 400 mg/100 mg filmcoated, Film-coated tablet, Epclusa 400 mg / 100 mg tablets | Gilead Sciences, Inc., Gilead Sciences, Inc. | Chronic Hepatitis C virus infection, Hepatitis C, Diseases [C] - Virus Diseases [C02] | | | | |
NCT03702218: Hepatitis C Positive Donor Into Hepatitis C Negative Recipients |
|
|
| Withdrawn | 1 | 0 | US | Direct Acting Antivirals | University of Maryland, Baltimore | Hepatitis C | 07/19 | 07/19 | | |
| Active, not recruiting | 1 | 26 | Canada | Sofosbuvir-velpatasvir (400 mg/100 mg), Epclusa, Ex Vivo Lung Perfusion (EVLP), Normothermic EVLP | University Health Network, Toronto, Gilead Sciences | Lung Transplant Infection, Hepatitis C | 01/20 | 12/24 | | |
NCT03249194: Hepatitis C Virus Donor Positive Kidney Transplantation for Hepatitis C Virus Negative Recipients |
|
|
| Completed | 1 | 25 | US | Direct acting Anti-Viral Therapy using Epclusa or Zepatier, Epclusa, Zepatier | Virginia Commonwealth University | Kidney Transplant, Hepatitis C | 03/20 | 03/20 | | |
| Completed | 1 | 10 | US | Epclusa, Procedure, Sofosbuvir/velpatasvir | Pablo Sanchez | Hepatitis C, Lung Transplant | 09/21 | 04/22 | | |
NCT04382404: Treatment of Chronic Hepatitis C During Pregnancy With Sofosbuvir/Velpatasvir |
|
|
| Completed | 1 | 11 | US | Sofosbuvir-Velpatasvir Drug Combination, Epclusa | Catherine Anne Chappell, Gilead Sciences, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Hepatitis C, Chronic | 10/23 | 10/23 | | |
| Not yet recruiting | 1 | 3040 | NA | sofosbuvir/velpatasvir (SOF/VEL), Shortened read time of rapid diagnostic test for hepatitis C virus., OraQuick® HCV RDT | Médecins du Monde, UNITAID, Burnet Institute, University of Bristol, International Network of People who Use Drugs | Hepatitis C, RDT | 12/26 | 12/26 | | |
